uniQure Announces Results For Fourth Quarter And Financial Year 2014
Amsterdam, the Netherlands, April 6, 2015 — uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced unaudited results for the fourth quarter and year ending December 31, 2014, and provided an update on multiple gene therapy programs.
2014 and Other Recent Updates
Strategic Collaboration with Bristol-Myers Squibb
Bristol-Myers Squibb Company and uniQure announced today an agreement that provides Bristol-Myers Squibb with exclusive access to uniQure’s gene therapy technology platform for multiple targets in the cardiovascular space. The collaboration includes uniQure’s proprietary congestive heart failure program targeting S100A1, a calcium sensor and master regulator of heart function, and the companies will collaborate on up to nine other gene therapy targets addressing a broad range of cardiovascular disease and other target-specific disease areas.
Help employers find you! Check out all the jobs and post your resume.
2014 and Other Recent Updates
Strategic Collaboration with Bristol-Myers Squibb
Bristol-Myers Squibb Company and uniQure announced today an agreement that provides Bristol-Myers Squibb with exclusive access to uniQure’s gene therapy technology platform for multiple targets in the cardiovascular space. The collaboration includes uniQure’s proprietary congestive heart failure program targeting S100A1, a calcium sensor and master regulator of heart function, and the companies will collaborate on up to nine other gene therapy targets addressing a broad range of cardiovascular disease and other target-specific disease areas.
Help employers find you! Check out all the jobs and post your resume.